

**MICRO-X RECEIVES \$3.9M R&D TAX INCENTIVE**

**Adelaide, Australia, 7 December 2022:** Australian hi-tech company Micro-X Ltd (ASX:MX1) (Micro-X or the Company), a leader in cold cathode x-ray technology for health and security markets globally, is pleased to advise that it has received a Research & Development (R&D) Tax Incentive, net of income tax payable, of \$3.9 million for the financial year ended 30 June 2022.

The cash rebate from the Australian Tax Office is related to the expenditure on eligible Australian R&D activities conducted during the 2021/2022 financial year.

This ASX announcement is authorised by Kingsley Hall, Company Secretary of Micro-X

– ENDS –

**About Micro-X**

Micro-X Limited (the Company) is an ASX listed hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube (CNT) emitter technology. The electronic control of emitters with this technology enables x-ray products with significant reduction in size, weight, and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security and defence applications. Micro-X has a fully vertically integrated design and production facility in Adelaide, Australia. A growing technical and commercial team based in Seattle is rapidly expanding Micro-X's US business.

Micro-X's product portfolio is built in four, high margin, product lines in health and security. The first commercial mobile digital radiology products are currently sold for diagnostic imaging in global healthcare, military, and veterinary applications. An X-ray Camera for security imaging of Improvised Explosive Devices is in advanced development. The US Department of Homeland Security has selected Micro-X to design a next-generation Airport Checkpoint Portal with self-service x-ray. A miniature brain CT imager for pre-hospital stroke diagnosis in ambulances, is being developed with funding from the Australian Government's Medical Research Future Fund.

For more information visit: [www.micro-x.com](http://www.micro-x.com)

**CONTACTS**

| Micro-X Limited  | Investor Enquiries   |
|--|--|
| Peter Rowland, Managing Director<br>Kingsley Hall, CFO and Company Secretary<br>Rebecca Puddy, Head of Corporate Communications<br><br>Tel: +61 8 7099 3966<br>E: <a href="mailto:admin@micro-x.com">admin@micro-x.com</a> | David Allen / John Granger<br>Hawkesbury Partners<br>Tel: +61 2 9103 9494<br>E: <a href="mailto:dallen@hawkesburypartners.com">dallen@hawkesburypartners.com</a><br><a href="mailto:jgranger@hawkesburypartners.com">jgranger@hawkesburypartners.com</a> |